Arena Pharma (ARNA) Tops Q3 EPS by 2c; Issues Corp., R&D, BELVIQ Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
RBC Capital Slashes PT on Arena Pharma (ARNA) to $2 Following Q3 Report, Update
November 11, 2015 8:53 AM ESTRBC Capital cuts its price target on Sector Perform-rated Arena Pharma (Nasdaq: ARNA) from $5 to $2 following Q3 results issued Tuesday night.
Analyst Simos Simeonidis commented, Arena reported 3Q15 earnings and provided additional color on the recently announced changes in strategic focus, following... More
Needham & Company Updates Ests on Arena Pharma (ARNA) Following Q3 Results; Maintains 'Hold' Rating
November 11, 2015 6:55 AM ESTNeedham & Company affirms Arena Pharma (Nasdaq: ARNA) at Hold following the company's Q3 reprot on Tuesday night.
Analyst Alan Carr summarized: The company reported $4.9M in 3Q15 Belviq revenue from collaborators Eisai and Ildong, compared to our $4.7M estimate. Eisai... More
